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AbsTrACT
background Despite simpler regimens than vitamin 
K antagonists (VKas) for stroke prevention in atrial 
fibrillation (aF), adherence (taking drugs as prescribed) 
and persistence (continuation of drugs) to direct oral 
anticoagulants are suboptimal, yet understudied in 
electronic health records (ehrs).
Objective We investigated (1) time trends at individual 
and system levels, and (2) the risk factors for and 
associations between adherence and persistence.
Methods in UK primary care ehr (The health 
information network 2011–2016), we investigated 
adherence and persistence at 1 year for oral 
anticoagulants (Oacs) in adults with incident aF. 
Baseline characteristics were analysed by Oac and 
adherence/persistence status. risk factors for non- 
adherence and non- persistence were assessed using 
cox and logistic regression. Patterns of adherence and 
persistence were analysed.
results among 36 652 individuals with 
incident aF, cardiovascular comorbidities (median 
cha2Ds2Vasc[congestive heart failure, hypertension, 
age≥75 years, Diabetes mellitus, stroke, Vascular disease, 
age 65-74 years, sex category] 3) and polypharmacy 
(median number of drugs 6) were common. adherence 
was 55.2% (95% ci 54.6 to 55.7), 51.2% (95% ci 50.6 
to 51.8), 66.5% (95% ci 63.7 to 69.2), 63.1% (95% 
ci 61.8 to 64.4) and 64.7% (95% ci 63.2 to 66.1) for 
all Oacs, VKa, dabigatran, rivaroxaban and apixaban. 
One- year persistence was 65.9% (95% ci 65.4 to 66.5), 
63.4% (95% ci 62.8 to 64.0), 61.4% (95% ci 58.3 
to 64.2), 72.3% (95% ci 70.9 to 73.7) and 78.7% 
(95% ci 77.1 to 80.1) for all Oacs, VKa, dabigatran, 
rivaroxaban and apixaban. risk of non- adherence and 
non- persistence increased over time at individual and 
system levels. increasing comorbidity was associated 
with reduced risk of non- adherence and non- persistence 
across all Oacs. Overall rates of ’primary non- adherence’ 
(stopping after first prescription), ’non- adherent non- 
persistence’ and ’persistent adherence’ were 3.5%, 
26.5% and 40.2%, differing across Oacs.
Conclusions adherence and persistence to Oacs 
are low at 1 year with heterogeneity across drugs 
and over time at individual and system levels. Better 
understanding of contributory factors will inform 
interventions to improve adherence and persistence 
across Oacs in individuals and populations.
InTrOduCTIOn
For 60 years, vitamin K antagonists (VKAs), mainly 
warfarin, dominated stroke prevention in atrial 
fibrillation (AF), the most common arrhythmia 
globally.1 2 Successive approval of four direct oral 
anticoagulants (DOACs: dabigatran,3 apixaban,4 
rivaroxaban5 and edoxaban6) changed the land-
scape, with early adoption in guidelines7 8 and 
quality improvement initiatives.9 DOACs are often 
preferred over VKA due to reduced international 
normalised ratio (INR) monitoring, but only if OAC 
services are fully decommissioned and DOACs are 
taken appropriately. Paradoxically, removal of 
the need for INR monitoring also removes addi-
tional patient–clinician engagement that encour-
ages adherence (taking drugs as prescribed) and 
persistence (continuation of therapy),10 both perti-
nent to oral anticoagulants (OACs) with a lifelong 
therapeutic indication.
Despite its importance in the context of popu-
lation ageing, declining cognitive function, multi-
morbidity and polypharmacy, adherence was 
unreported in trials of DOACs,3–6 despite short 
half- lives, particularly dabigatran and apixaban 
which require dosing two times per day.11 Reported 
trial persistence was highest for dabigatran (79.3% 
at low dose) and lowest for edoxaban (65.6% at 
high dose)3–6 (online supplementary web table 
1). All DOACs have proven efficacy compared 
with VKA, although at much lower time in ther-
apeutic range (TTR) in trials than usual clinical 
practice, but ‘head- to- head’ DOAC trial compar-
isons are unlikely. However, several studies have 
shown suboptimal adherence and persistence for 
DOACs in different countries and settings, even 
compared with VKA, and effective interventions 
are lacking.12–14 Underlying causes include factors 
at social, economic, health system, clinician and 
patient levels. Although all patient- level factors 
are not captured, electronic health records (EHRs) 
allow population- level studies of adherence and 
persistence together across all DOACs in the same 
data set, which are rare.13
Only one study to date has considered all metrics 
of drug utilisation (‘initiation’, ‘implementation’ 
and ‘discontinuation’) together rather than ‘adher-
ence’ or ‘persistence’ in isolation15 for OAC in 
AF.13 Steps in drug utilisation may be described 
as the ‘prescription- persistence cascade’ (from 
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‘recommendation’ to ‘persistence’/’continuation’), estimable 
from EHR. For OAC in AF, the steps are ‘recommendation’ 
(eligible for OAC), ‘initial prescription’ (≥1 OAC prescrip-
tion), ‘dispensing’ (no EHR data), ‘initiation by patient’ (no 
EHR data), ‘adherence’/‘implementation’ (adherent to OAC) 
and ‘persistence’/‘continuation’ (persistent to OAC). Interac-
tion between adherence and persistence is often overlooked, for 
example, ‘persistent and non- adherent’ (ie, continuing medica-
tions but not taking as prescribed) versus ‘non- persistent and 
non- adherent’ (ie, discontinued medications and also not taking 
as prescribed).
The UK has universal primary healthcare, enabling large- 
scale, representative data sets where uptake, adherence and 
persistence for different DOACs can be studied. We used The 
Health Improvement Network (THIN) database in the UK to 
investigate adherence and persistence for OACs in individuals 
with AF, focusing on (1) time trends since DOAC introduction at 
health system level and after initiation in individuals; (2) relative 
impact of sociodemographic and baseline risk factors and treat-
ment characteristics; and (3) associations between adherence 
and persistence.
MeTHOds
The study conformed to the Strengthening the Reporting of 
Observational Studies in Epidemiology recommendations.16
data source
The THIN database includes longitudinal, anonymised EHRs 
from over 500 UK general practices using Vision software (INPS, 
www. inps4. co. uk/), representative of the UK population.17
study population
Our retrospective cohort included individuals aged ≥18 years 
with first- ever, non- valvular AF diagnosis between January 2011 
and December 2016 and first prescription of VKA/DOAC on 
or after the date of AF diagnosis. The date of first prescription 
became the index date. For inclusion, patients needed ≥90 days 
of follow- up. Individuals with ≥1 prescription of VKA/DOAC 
were eligible for inclusion in adherence/persistence analyses. 
Exclusion criteria were taking OAC for other indications (eg, 
deep vein thrombosis and pulmonary embolism). Follow- up was 
until outcome event, death, the patient leaving the database or 
the most recent data upload.
baseline covariates
Baseline factors were assessed: demographics (age, sex, Townsend 
Deprivation Index quintile level 1—the least deprived category), 
comorbidities (heart failure, hypertension, diabetes mellitus, 
stroke/transient ischaemic attack, vascular disease, liver disease, 
hypercholesterolaemia, ie, on statin and/or had hypercholes-
terolaemia), social history (alcohol misuse, smoking status) and 
drug history (aspirin, statin, blood pressure- lowering drugs, 
and mean number of drugs including OAC, prescribed in ≤365 
days until, but not including, the episode start date). CHA2DS-
2VASc (Congestive heart failure, Hypertension, Age≥75 years, 
Diabetes mellitus, Stroke, Vascular disease, Age 65-74 years, Sex 
category18) and ‘HASBLED-1’ (rather than HASBLED (Hyper-
tension,Abnormal renal/liver function, Stroke, Bleeding, Labile 
INR, Elderly, Drugs or alcohol19), since INR and ‘labile INR’ 
were not available) scores were calculated from available vari-
ables and categorised based on current guidelines.
Outcomes
Outcomes were adherence to and persistence with OACs. Adher-
ence was estimated by proportion of days covered (PDC) over 
the year following first prescription of VKA/DOAC, which more 
accurately reflects patient behaviour and treatment continuity 
than other adherence measures20:
  
Each prescription was assumed to last 30 days, unless a new 
prescription was issued within 30 days, in which case the original 
prescription’s duration was assumed to equal the gap between the 
two prescriptions. Patients with only one OAC prescription were 
classed as ‘missing’ and not included in the estimation. Impact 
of varying PDC threshold to 70% and 90% was examined for 
all OACs. Adherence was defined as PDC >80% like previous 
studies21 and produced more stable estimates. Individuals 
prescribed VKA/DOAC were deemed persistent until a prescrip-
tion gap >90 days on that or an alternative OAC (‘switch’), in 
which case they were non- persistent, or there was no further 
longitudinal data (in which case persistence status was unknown 
beyond that time). For each DOAC, proportion of switching to 
VKA or another DOAC was analysed over 12 months. Impact of 
varying prescription gaps to 60 and 120 days was examined for 
all OACs. Like previous studies,22 the 90- day prescription gap 
was used, providing more stable estimates. As prescription gaps 
lengthened, persistence improved more with VKA than DOACs 
(online supplementary web table 1).
statistical analysis
Baseline characteristics were analysed by OAC. If any OAC/
DOAC group consisted of <100 individuals, sample size was 
deemed too low to undertake meaningful analysis. Persistence 
was estimated using Kaplan- Meier product- limit estimator. 
Crude persistence for different OACs was estimated through 
survival life tables (adopting different prescription gaps) and 
ascertaining the number and percentage (95% CI) of patients 
still in the study (ie, persistent or uncensored) after 1 year. After 
stratification by adherence/persistence status at 12 months, base-
line characteristics were determined. χ2 test and analysis of vari-
ance test were used for categorical and continuous covariates, 
respectively. Relative effects of OACs on non- adherence and 
non- persistence were modelled using univariable and multivari-
able logistic regression and Cox proportional hazard regression 
(simple and multiple), respectively. For multivariable analyses, 
we adjusted for date of first OAC prescription (relative to study 
start date), CHA2DS2VASc, HASBLED-1, Townsend Deprivation 
Index quintile and number of drugs. Optimal adjustments for 
CHA2DS2VASc, HASBLED-1, number of drugs and date of first 
OAC prescription were investigated using continuous variables 
(including potential quadratic effects) or clinically appropriate 
categorisation. Models were compared using Bayesian infor-
mation criterion (BIC) and the optimal model chosen based on 
the lowest BIC. For Cox regression, the proportional hazards 
assumption was investigated by adding interactions with ‘time 
in study’. Interactions were included if they improved the model 
(by BIC criterion). For non- adherence, a sensitivity analysis 
was performed in those who had ≥6 months’ potential OAC 
coverage (ie, ≥6 months between date of first prescription 
and date of last prescription plus 30 days) and ≥12 months’ 
OAC potential coverage to reduce potential bias in estimated 
adherence in short treatment periods, leading to an overesti-
mate of PDC (online supplementary web tables 2a and 2b). For 
non- persistence, two sensitivity analyses were based around the 
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Figure 1 Flow diagram of study population for adherence and persistence analyses. AF, atrial fibrillation; OAC, oral anticoagulant; VKA, vitamin K 
antagonist.
chosen Cox regression model by (1) adding interactions (linear; 
linear and quadratic) between OAC and timing of first OAC 
prescription (relative to study initiation); and (2) reclassifying 
those switching to another OAC as censored (cessation of obser-
vation) rather than non- persistent to first OAC prescribed.
resulTs
Among 4 354 740 individuals, 154 180 with AF were identified, 
of whom 36 652 met the inclusion criteria for analysis: VKA 
(n=25 008, 68.2%), dabigatran (n=1285, 3.5%), rivaroxaban 
(n=5855, 16.0%) and apixaban (n=4504, 12.3%) (figure 1). 
Major exclusions were no new AF diagnosis (n=95 237) and 
absence of OAC prescription data (n=17 065). Edoxaban was 
UK- approved in September 2015, leading to inadequate sample 
size for analysis (n=45) during the study period.
The study population had a mean age of 74.4 (SD 10.5) 
years and 45% were female. Cardiovascular comorbidities were 
common: hypertension (62.6%) and hypercholesterolaemia 
(71.8%), with a median CHA2DS2VASc of 3 (IQR 2–4). Poly-
pharmacy was common (number of drugs: median 6, IQR 4–7). 
Individuals on dabigatran had lower CHA2DS2VASc scores, rates 
of hypertension and current smoking, with no other significant 
baseline differences across different OACs (table 1).
Adherence
Adherence was 55.2% (54.6–55.7) overall and 51.2% (50.6–
51.8), 66.5% (63.7–69.2), 63.1% (61.8–64.4) and 64.7 
(63.2–66.1) for VKA, dabigatran, rivaroxaban and apixaban, 
respectively (online supplementary web table 1).
In univariable analysis, the likelihood of non- adherence with 
DOACs was lower than with VKA (OR 0.53, 0.47–0.60; 0.61, 
0.58–0.65; and 0.57, 0.54–0.61 for dabigatran, rivaroxaban 
and apixaban, respectively) (table 2 and online supplemen-
tary web table 2d). In multivariable analysis, the likelihood of 
non- adherence was similar for dabigatran (0.54, 0.48–0.62), 
but higher for rivaroxaban (0.76, 0.71–0.82) and apixaban 
(0.77, 0.71–0.84). Increasing comorbidity (by CHA2DS2VASc) 
was associated with decreased likelihood of non- adherence 
(1.00, 0.93–1.08; 0.94, 0.88–1.01; and 0.81, 0.74–0.89 for 
CHA2DS2VASc scores 2, 3–4 and 5–9, respectively, compared 
with CHA2DS2VASc scores 0–1), but not for HASBLED-1 score 
(0.98, 0.93–1.05 for HASBLED-1 scores ≥3, compared with 
HASBLED-1 scores 0–2). The number of drugs and Townsend 
quintile were not associated with non- adherence (table 2). Age 
≥75 years, diabetes, female gender and anaemia were associ-
ated with reduced risk of non- adherence, while hypertension 
and vascular disease were associated with increased risk (online 
supplementary web table 2c). Non- adherence was non- linearly 
associated with time since introduction of DOACs, increasing 
for approximately 2 years (to early 2013) before starting to 
decrease, returning to its original level by early 2015 (online 
supplementary web figure 1a) and then dropping below its orig-
inal level. Baseline characteristics by adherence status are shown 
in online supplementary web table 4. Online supplementary web 
table 2e illustrates no important differences in the effect of time 
since introduction of DOACs between different OACs (online 
supplementary web figure 1b). Sensitivity analysis in only those 
who had at least 6 or 12 months of OAC prescriptions showed 
little impact on relative non- adherence for dabigatran and VKA; 
however, estimated ORs for rivaroxaban and apixaban both 
decreased to 0.65 (for 12- month restriction) (online supplemen-
tary web tables 2a and 2b).
Persistence
One- year persistence was 65.9% (65.4–66.5) overall and 63.4% 
(62.8–64.0), 61.4% (58.3–64.2), 72.3% (70.9–73.7) and 78.7% 
(77.1–80.1) for VKA, dabigatran, rivaroxaban and apixaban, 
respectively. Persistence reduced over 3 years for all OACs and 
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Table 1 Baseline characteristics of study population
Overall (n=36 652)
VKA
(n=25 008) dabigatran (n=1285) rivaroxaban (n=5855) Apixaban (n=4504) P value
Characteristics, n (%)
Age, mean (SD) 74.4 (10.5) 74.3 (10.2) 73.4 (11.2) 74.8 (11.0) 74.8 (11.0) <0.001
Female 16 494 (45.0) 11 186 (44.7) 517 (40.2) 2671 (45.6) 2120 (47.1) <0.001
Townsend quintile, median (IQR) 2 (1–4) 2 (1–4) 2 (1–3) 3 (1–4) 3 (1–4)
  1 8862 (24.2) 6124 (24.5) 345 (26.9) 1347 (23.0) 1046 (23.2) <0.001
  2 8269 (22.6) 5706 (22.8) 321 (25.0) 1300 (22.2) 942 (20.9)
  3 7330 (20.0) 4964 (19.9) 270 (21.0) 1231 (21.0) 865 (19.2)
  4 5864 (16.0) 4065 (16.3) 185 (14.4) 897 (15.3) 717 (15.9)
  5 3800 (10.4) 2540 (10.2) 98 (7.6) 574 (9.8) 588 (13.1)
  Missing 2527 (6.9) 1609 (6.4) 66 (5.1) 506 (8.6) 346 (7.7)
Comorbidities, n (%)
Heart failure 2700 (7.4) 1908 (7.6) 79 (6.2) 387 (6.6) 326 (7.2) 0.016
Hypertension 22 955 (62.6) 15 824 (63.3) 751 (58.4) 3612 (61.7) 2768 (61.5) <0.001
Diabetes mellitus 6691 (18.3) 4594 (18.4) 210 (16.3) 1058 (18.1) 829 (18.4) 0.31
Stroke/transient ischaemic attack 4622 (12.6) 3096 (12.4) 160 (12.5) 735 (12.6) 631 (14.0) 0.026
Vascular disease 4793 (13.1) 3316 (13.3) 149 (11.6) 717 (12.3) 611 (13.6) 0.052
Alcohol misuse 977 (2.7) 589 (2.4) 36 (2.8) 175 (3.0) 177 (3.9) <0.001
Chronic kidney disease 7844 (21.4) 5426 (21.7) 221 (17.2) 1229 (21.0) 968 (21.5) 0.002
Liver disease 100 (0.3) 67 (0.3) 4 (0.3) 15 (0.3) 14 (0.3) 0.94
Hypercholesterolaemia 26 328 (71.8) 17 979 (71.9) 915 (71.2) 4172 (71.3) 3262 (72.4) 0.56
Smoking status
  Current smoker 3374 (9.2) 2272 (9.1) 103 (8.0) 585 (10.0) 414 (9.2) <0.001
  Ex- smoker 13 928 (38.0) 9711 (38.8) 484 (37.7) 2125 (36.3) 1608 (35.7)
  Never smoked 18 484 (50.4) 12 472 (49.9) 666 (51.8) 2993 (51.1) 2353 (52.2)
  Not indicated 866 (2.4) 553 (2.2) 32 (2.5) 152 (2.6) 129 (2.9)
Risk scores, n (%)
  CHA2DS2- VASc
  0–1 5856 (16.0) 3887 (15.5) 263 (20.5) 984 (16.8) 722 (16.0) <0.001
  2 7192 (19.6) 4939 (19.8) 279 (21.7) 1106 (18.9) 868 (19.3)
  3–4 17 894 (48.8) 12 324 (49.3) 571 (44.4) 2850 (48.7) 2149 (47.7)
  5–9 5710 (15.6) 3858 (15.4) 172 (13.4) 915 (15.6) 765 (17.0)
  HASBLED-1
  0–2 28 279 (77.2) 19 298 (77.2) 1047 (81.5) 4508 (77.0) 3426 (76.1) <0.001
  3–8 8373 (22.8) 5710 (22.8) 238 (18.5) 1347 (23.0) 1078 (23.9)
Drugs, n (%)
Aspirin 20 510 (56.0) 14 175 (56.7) 683 (53.2) 3116 (53.2) 2536 (56.3) <0.001
Statin 17 185 (46.9) 11 803 (47.2) 551 (42.9) 2651 (45.3) 2180 (48.4) <0.001
Blood pressure- lowering drugs 29 136 (79.5) 20 007 (80.0) 961 (74.8) 4563 (77.9) 3605 (80.0) <0.001
Number of drugs, mean (SD) 5.5 (2.2) 5.5 (2.2) 5.3 (2.2) 5.5 (2.2) 5.7 (2.2) <0.001
CHA2DS2- VASc, Congestive heart failure; Hypertension, Age≥75 years; Diabetes mellitus; Stroke, Vascular disease; Age 65-74 years; Sex category ; HASBLED-1, Hypertension; 
Abnormal renal/liver function; Stroke; Bleeding; Labile INR; Elderly; Drugs or alcohol; VKA, vitamin K antagonist.
was highest for apixaban and lowest for VKA and dabigatran 
(figure 2).
In univariable analysis, apixaban had the lowest (HR 0.53, 
0.50–0.57) and dabigatran had the highest (HR 1.02, 0.93–
1.11) risk of non- persistence at 1 year, relative to VKA. Table 3 
illustrates the optimal multivariable model, where the effects 
of CHA2DS2VASc and OAC required an interaction term with 
time since first OAC prescription. The interaction between time 
and date of first prescription shows that immediately following 
first prescription, apixaban still had the lowest risk (0.53, 0.46–
0.60) and dabigatran the highest (1.24, 1.08–1.42), relative to 
VKA. The risk of non- persistence did not change over time for 
apixaban (0.91, 0.78–1.06 per year), but reduced over time for 
dabigatran (0.75, 0.65–0.86 per year) and rivaroxaban (0.69, 
0.62–0.77 per year). Immediately after the first prescription, 
increasing comorbidity, when measured by CHA2DS2VASc score, 
was associated with reduced risk of non- persistence (0.71, 0.66–
0.76; 0.66, 0.62–0.71; and 0.69, 0.63–0.76 for CHA2DS2VASc 
scores 2, 3–4 and 5–9, respectively, compared with CHA2DS-
2VASc scores 0–1). However, this risk was lessened over time 
(1.05, 0.99–1.12 and 1.13, 1.06–1.20 per year for CHA2DS-
2VASc scores 2 and 5–9, respectively). There was no signifi-
cant effect of HASBLED-1 (1.04, 0.99–1.08 for HASBLED-1 
scores ≥3, compared with HASBLED-1 scores 0–2), nor for the 
number of drugs or Townsend quintile (table 3). Overall, risk 
of non- persistence increased from 2011 until 2016 (1.03, 1.01–
1.05 per year). Heart failure, vascular disease, chronic kidney 
disease, prior bleeding and alcohol misuse were associated with 
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Table 2 Likelihood of non- adherence by oral anticoagulant
n
univariable
Or (95% CI)
Multivariable
Or (95% CI)
P value33 960 31 615
VKA 1.00 (–) 1.00 (–)
Dabigatran 0.53 (0.47 
to 0.60)
0.54 (0.48 to 0.62) <0.001
Rivaroxaban 0.61 (0.58 
to 0.65)
0.76 (0.71 to 0.82)
Apixaban 0.57 (0.54 
to 0.61)
0.77 (0.71 to 0.84)
CHA2DS2VASc
  0–1 1.00 (–)
  2 1.00 (0.93 to 1.08) <0.001
  3–4 0.94 (0.88 to 1.01)
  5–9 0.81 (0.74 to 0.89)
HASBLED-1
  0–2 1.00 (–)
  3–9 0.98 (0.93 to 1.05) 0.62
Number of drugs
Continuous/Linear 0.99 (0.98 to 1.00) 0.067
Townsend quintile
  1 1.00 (–)
  2 0.93 (0.87 to 0.99) <0.001
  3 0.86 (0.80 to 0.91)
  4 0.91 (0.85 to 0.97)
  5 0.86 (0.80 to 0.94)
Date of first prescription* 
(years after 1 January 
2011)
Continuous/Linear 1.29 (1.22 to 1.37) <0.001
Continuous/Quadratic 0.94 (0.93 to 0.95)
BIC 46 263.63 42 880.41
*Time difference (in years) between the date of the first ever OAC prescription for each 
patient and the start date of the study (1 January 2011). This suggests that the maximum 
effect of calendar time occurs at −ln(1.29)(2×/ln(0.94))=2.13 years.
BIC, Bayes information criterion; CHA2DS2- VASc, Congestive heart failure, Hypertension, 
Age≥75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65-74 years, Sex category 
; HASBLED-1, Hypertension; Abnormal renal/liver function; Stroke; Bleeding; Labile INR; 
Elderly; Drugs or alcohol; OAC, oral anticoagulant; VKA, vitamin K antagonist.
Figure 2 Kaplan- Meier analysis of persistence over time. OAC, oral 
anticoagulant; VKA, vitamin K antagonist.
Table 3 Risk of non- persistence by oral anticoagulant
n
univariable
Hr (95% CI)
Multivariable
Hr (95% CI)
36 636 34 109
OAC (effect on first prescribing)
  VKA 1.00 (–) 1.00 (–)
  Dabigatran 1.02 (0.93 to 1.11) 1.24 (1.08 to 1.42)
  Rivaroxaban 0.71 (0.67 to 0.74) 0.85 (0.77 to 0.93)
  Apixaban 0.53 (0.50 to 0.57) 0.53 (0.46 to 0.60)
Time- dependent effect of OAC (per year of prescriptions)
  VKA 1.00 (–)
  Dabigatran 0.75 (0.65 to 0.86)
  Rivaroxaban 0.69 (0.62 to 0.77)
  Apixaban 0.91 (0.78 to 1.06)
CHA2DS2VASc (effect on first prescribing)
  0–1 1.00 (–)
  2 0.71 (0.66 to 0.76)
  3–4 0.66 (0.62 to 0.71)
  5–9 0.69 (0.63 to 0.76)
Time- dependent effect of CHA2DS2VASc (per year of prescriptions)
  0–1 1.00 (–)
  2 1.05 (0.99 to 1.12)
  3–4 1.12 (1.07 to 1.18)
  5–9 1.13 (1.06 to 1.20)
HASBLED-1
  0–2 1.00 (–)
  3–9 1.04 (0.99 to 1.08)
Number of drugs 1.00 (0.99 to 1.01)
Townsend quintile
  1 1.00 (–)
  2 0.99 (0.95 to 1.03)
  3 0.95 (0.91 to 1.00)
  4 0.97 (0.93 to 1.02)
  5 0.97 (0.92 to 1.03)
Date of first prescription* (years after 1 
January 2011)
1.03 (1.02 to 1.05)
*Time difference (in years) between the date of the first ever OAC prescription for each patient and the 
start date of the study (1 January 2011) .
CHA2DS2- VASc, Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, Stroke, 
Vascular disease, Age 65-74 years, Sex category; HASBLED-1, Hypertension; Abnormal renal/liver 
function; Stroke; Bleeding; Labile INR; Elderly; Drugs or alcohol; OAC, oral anticoagulant; VKA, vitamin 
K antagonist.
increased risk of non- persistence, while hypertension and age 
>65 years were associated with reduced risk. Non- persistence 
was more likely for dabigatran soon after initiation, but the effect 
relative to VKA and to apixaban declined over the period of an individual’s prescription, although this did not happen relative 
to rivaroxaban (Online supplementary web tables 5a and 5b). 
Baseline characteristics are presented by 1- year persistence status 
in online supplementary web table 6.
Persistence and adherence
Of 36 652 individuals, 31.0% had <1 year of data, and of 
these 15.8% had primary non- adherence, 27.9% were non- 
adherent and 56.2% were adherent. Among 25 263 individuals 
with ≥1 year of data, primary non- adherence (3.5%) was less 
common than non- adherent, non- persistent (21.2%), adherent, 
non- persistent (8.6%), non- adherent, persistent (26.5%), and 
persistent, adherent (40.2%). Differences between OACs were 
significant (p<0.001). Primary non- adherence was highest with 
dabigatran (7.8%) and lowest (2.7%) with apixaban, while 
persistent adherence was highest with apixaban (50.7%) and 
lowest with VKA (38.2%). Non- adherent, non- persistence was 
greatest with VKA (23.4%) and least with apixaban (12.4%). 
Non- adherent persistence was highest with apixaban (29.0%) 
and lowest with dabigatran (19.5%) (table 4).
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Table 4 Adherence and persistence by oral anticoagulant
Overall VKA dabigatran rivaroxaban Apixaban
Total, n (%) 36 652 25 008 1285 5855 4504
Zero follow- up 16 (0.04) 7 (0.03) 1 (0.08) 5 (0.09) 3 (0.07)
Total <1 year of data 11 373 (31.0) 5307 (21.2) 441 (34.3) 3014 (51.5) 2611 (58.0)
Primary non- adherence 1800 (15.8) 818 (15.4) 78 (17) 531 (17.6) 373 (14.3)
Non- adherent 3178 (27.9) 1654 (31.2) 94 (21.3) 771 (25.6) 659 (25.2)
Adherent 6395 (56.2) 2835 (53.4) 269 (61.0) 1712 (56.8) 1579 (60.5)
Total ≥1 year of data 25 263 (68.9) 19 694 (78.8) 843 (65.6) 2836 (48.4) 1890 (42.0)
Primary non- adherence 876 (3.5) 631 (3.2) 66 (7.8) 128 (4.5) 51 (2.7)
Non- adherent, non- 
persistent
5352 (21.2) 4616 (23.4) 124 (14.7) 378 (13.3) 234 (12.4)
Adherent, non- persistent 2173 (8.6) 1711 (8.7) 132 (15.7) 232 (8.2) 98 (5.2)
Non- adherent, persistent 6699 (26.5) 5221 (26.5) 164 (19.5) 766 (27.0) 548 (29.0)
Persistent, adherent 10 163 (40.2) 7515 (38.2) 357 (42.3) 1332 (47.0) 959 (50.7)
VKA, vitamin K antagonist.
switching
In non- persistent individuals, switching rates were 20.3%, 
18.8%, 40.3%, 27.0% and 18.5% for all OACs, VKA, dabigatran, 
rivaroxaban and apixaban, respectively. In primary non- adherent 
individuals, the corresponding rates were 45.2%, 40.9%, 69.1%, 
51.2% and 44.7%, respectively (online supplementary web table 
7). When ‘switching’ was censored rather than ‘non- persistent’, 
differences between OACs were more consistent over time (since 
first prescription) and non- persistence was generally lower for 
dabigatran than VKA, with an increasing trend in the difference 
with time on OAC. The effect was less for other DOACs relative 
to VKA (online supplementary web figure 1 and web table 8).
dIsCussIOn
In this study of long- term persistence and adherence across all 
OACs in AF, we have four findings. First, primary non- adherence 
is uncommon (3.5%), and over time on a DOAC the likelihood 
of non- adherence and non- persistence increases. Second, the 
proportion of individuals on OACs who are both adherent and 
persistent at 1 year is low (40.2%), with heterogeneity across 
different OACs. Third, population- level time trends in adher-
ence and persistence exist after new drugs (DOACs in this case) 
are introduced. Fourth, increased comorbidities were associated 
with reduced risk of non- adherence and non- persistence for 
DOACs, but the number of drugs was not.
Observed rates of primary non- adherence for OAC are compa-
rable with a recent Spanish study using large- scale regional 
EHR.12 Primary non- adherence varies across different drugs, 
but our estimates appear lower than other chronic disease medi-
cations (≤20.8% for lipid- lowering drugs23). Rates are gener-
ally lower in European populations23 than in North America, 
probably due to greater provision of prescription medication in 
public- funded health systems. Our results suggest that improved 
adherence and persistence requires longer- term monitoring, 
rather than current strategies emphasising drug adherence 
postinitiation. Greater switching with dabigatran than other 
OACs may reflect greater discontinuation (due to dyspepsia 
or other side effects3) or prescription patterns favouring other 
DOACs.24
For drugs to be effective, both adherence and persistence are 
prerequisites. It is therefore concerning that adherent persistence 
at 1 year after initial prescription ranged from only 38.2% to 
50.7% for VKA and apixaban, respectively. Non- adherent, 
non- persistent individuals constituted 23.4% and 12.4% for 
users of VKA and apixaban, respectively (table 4). Adherence 
and persistence should be considered in combination, yet this is 
rare in both research and clinical practice.25 Furthermore, obser-
vations that non- adherent, persistence is more common than 
adherent, non- persistence and that these proportions vary by 
type of OAC highlight the need for measurement of both metrics 
and potential for personalising approaches to improved drug 
utilisation. Factors which influence choice of drug in the same 
class include pharmacodynamics, pharmacokinetic, tolerability 
and cost,26 to which adherence and persistence may be added.
DOACs are unusual for several new drugs in the same class 
entering the market in a short timeframe. Other examples are 
statins, antihypertensives and novel hypoglycaemic agents, but 
four new drugs in a 5- year period is extraordinary. DOACs have 
proven efficacy and effectiveness over VKA, and appropriate 
prescribing of OACs in AF has improved in the UK between 2000 
and 2016.27 However, there have been variations in prescription 
across DOACs over time.28 Our analyses add that when DOACs 
were first prescribed, persistence to all DOACs appears to have 
been initially higher than to VKA and in some cases increase 
further over time on the OAC, with clear differences between 
different OACs. Findings were sensitive to how switching of 
drugs was considered, with persistence to dabigatran, which had 
the highest rates of ‘switching’, appearing much lower than VKA 
when ‘switchers’ were classed as ‘non- persistent’ versus censored 
(‘no longer observed for that OAC’). Other possible reasons for 
differences between OACs include side effect profile, marketing 
strategies, and varying procurement and prescription practices. 
Adherence and persistence can have far- reaching implications on 
drug cost, effectiveness and policy at the population level29 and 
should be monitored at the population level.
Our findings are consistent with previous studies which have 
shown associations between polypharmacy12 30 and increased 
comorbidities25 and reduced risk of non- adherence or non- 
persistence for OACs and other cardiovascular medications. 
Understanding each of the multiple steps in the prescription- 
persistence cascade may aid design and implementation of better 
interventions to improve drug utilisation. In routine clinical 
practice, EHR- based methods may be used to highlight indi-
viduals at greater risk of non- adherence or non- persistence, for 
example, by suggesting that persistence should be more of a 
focus for improvement than adherence, or for monitoring long- 
term adherence/persistence.
The major strength of our analysis is consideration of the 
relationship between adherence and persistence together across 
all DOACs and VKA in the same population. As well as socio-
demographic, health and medication characteristics, the influ-
ence of time was also analysed. Even in large- scale data sets with 
125Banerjee a, et al. Heart 2020;106:119–126. doi:10.1136/heartjnl-2019-315307
Health care delivery, economics and global health care
Key messages
What is already known on this subject?
 ► Despite proven efficacy for stroke prevention in atrial 
fibrillation, adherence and persistence are suboptimal for oral 
anticoagulants (OACs).
 ► Adherence and persistence are rarely studied together in 
the same population across all anticoagulants, taking into 
account all baseline factors in electronic health records.
What might this study add?
 ► This is the first study evaluating the time trends, predictive 
factors and associations between adherence and persistence 
of anticoagulants in atrial fibrillation in a population- based 
study in electronic health records.
 ► Persistence and adherence to OACs are relatively low at 
1 year and there is heterogeneity across different OACs.
 ► There are significant variations over time that a patient is on 
a direct oral anticoagulant (DOAC), and population- level time 
trends in adherence and persistence after new drugs (DOACs 
in this case) are introduced.
How might this impact on clinical practice?
 ► Interventions should focus on improving adherence and 
persistence together and across drugs.
 ► These data may help to better understand the determinants 
of adherence and persistence, and to design and target 
interventions.
prescription data, there are several limitations. First, we did not 
have dispensing data, and therefore used previously validated 
methods to estimate adherence/persistence from prescription 
data. Our methods may be more uncertain for VKA than for 
DOACs (eg, differential impact of varying prescription gaps on 
persistence), possibly due to patients on warfarin often having 
longer duration prescriptions than DOACs. Second, missing 
prescription data meant that not all eligible individuals could 
be included due to incompleteness of follow- up. On the other 
hand, these are real- world data, which are routinely available 
and nationally representative. Third, relatively small numbers 
of patients could be included for DOACs, but numbers were 
comparable with other studies. Fourth, TTR would be a better 
measure of adherence for VKA but could not be estimated in 
our analysis due to lack of INR data (which also limited our 
HASBLED analysis). Finally, we focused on initial OAC 
prescription in OAC- naive patients to minimise bias in adher-
ence/persistence based on previous OAC use, but did not focus 
on second and subsequent OACs used, where there would be 
more bias and greater consideration of overall treatment pattern 
which requires consideration of multidrug, multidisease adher-
ence/persistence over time.
COnClusIOns
Our study shows changes in adherence and persistence for 
DOACs over time in AF. Since these are usually lifelong ther-
apies, more emphasis should be placed on long- term adherence 
and persistence in clinical practice and research. Standardisa-
tion is required for EHR methods of adherence and persistence 
estimation across drugs, diseases and data sets. Persistence and 
adherence may have different determinants and should be studied 
together in EHR. Better understanding of these factors will lead 
to interventions which are more likely to improve adherence and 
persistence at individual and population levels across OACs and 
other drugs. Postmarketing surveillance should take into account 
adherence and persistence particularly for multiple drugs in the 
same class where head- to- head trials are unlikely.
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